Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Completed
- Conditions
- CancerNauseaVomiting
- Registration Number
- NCT01440465
- Lead Sponsor
- Centre Francois Baclesse
- Brief Summary
The objective of this study was to evaluate the various parameters involved in the occurrence of nausea / vomiting during the first cycle of chemotherapy for solid tumors or hematologic among a group of chemotherapy-naive patients, despite anti standardized-emetics protocols.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Aged over 18 years
- With solid tumors or hematologic in first line chemotherapy, administered intravenously,
- Able to understand the meaning of the questions
- Having given their written consent to participate in the survey.
Exclusion Criteria
This does not concern patients who:
- Do not give their consent for participation
- Do not speak French
- Suffer from cognitive deficits
- Are under therapy
- Must receive a combination of radio-chemotherapy
- Present an occlusive syndrome
- Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s)
- Have been previously treated with chemotherapy
- Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors
- Pregnant or breastfeeding.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method acute nausea and vomiting 2 years acute nausea and vomiting and / or delayed measured by the tool of anti emetic MAT MASCC.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Centre de la Baie
🇫🇷Avranches, France
Centre hospitalier
🇫🇷Bayeux, France
Centre Maurice Tubiana
🇫🇷Caen, France
Centre François Baclesse
🇫🇷Caen, France
Centre hospitalier public du cotentin
🇫🇷Cherbourg-Octeville, France
Centre Jacques Monod
🇫🇷Flers, France
Centre de la Baie🇫🇷Avranches, France